Friday 6 November 2026 Export GMAB’s income statement to Excel — free account

Genmab A/S Sponsored ADR

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.

Revenue: +24.9%
EPS: −9.26%
Free cash flow: −7.69%

Quarter to June 2026, against a year earlier

53.63 0.89 +1.69%

Follow GMAB

Alert me

Market cap: $31.5B
P/E: 41.7×
Fwd P/E: 47.3×
Dividend yield: —
F-score: 4/9
Altman Z: 2.78
Beneish M: −3.00
Dividend safety: n/a

Overview

Genmab A/S Sponsored ADR (GMAB) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Genmab A/S Sponsored ADR (GMAB) trades at a P/S ratio of 7.9×. Over the past ten years it has ranged from 0.0× (September 2019) to 27.8× (December 2019); the current reading is higher than 56% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/GMAB/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Genmab A/S Sponsored ADR P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/GMAB/metrics/ps-ratio">Genmab A/S Sponsored ADR (GMAB) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	5.1×	19.89%
FY2024	4.3×	(51.04%)
FY2023	8.8×	(35.60%)
FY2022	13.6×	(28.98%)
FY2021	19.2×	12.05%
FY2020	17.1×	(2.12%)
FY2019	17.5×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/S ratio	Change
Jun 2026	4.1×	(6.01%)
Mar 2026	4.3×	(15.67%)
Dec 2025	5.1×	(2.35%)
Sep 2025	5.3×	39.54%
27 more quarters	Free account

Against its own ten years

Low 0.0× High 27.8×

Ten-year median 6.3×

Current reading's percentile 38

Company	P/S ratio
INCY Incyte Corporation compare	4.0×
ALNY Alnylam Pharmaceuticals, Inc. compare	4.2×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	6.6×
GMAB Genmab A/S Sponsored ADR	7.9×
BNTX BioNTech SE Sponsored ADR compare	7.9×
RPRX Royalty Pharma PLC compare	11.5×
INSM Insmed, Inc. compare	15.6×
RVMD Revolution Medicines, Inc. compare	185×
ROIV Roivant Sciences Ltd. compare	3,528×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Genmab A/S Sponsored ADR (GMAB) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on GMAB

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on GMAB

Stockrow Weekly